Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M.C. del Cañizo is active.

Publication


Featured researches published by M.C. del Cañizo.


Bone Marrow Transplantation | 1997

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

M. D. Caballero; Viñas Rubio; J. Rifón; Inmaculada Heras; Ramón García-Sanz; L Vazquez; Belén Vidriales; M.C. del Cañizo; Mercedes Corral; González M; Angel Leon; E. Jean-Paul; Eduardo Rocha; J.M. Moraleda; J. F. San Miguel

In the present paper, we evaluate tolerability, outcome and prognostic factors in patients with poor prognosis non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) when uniformly treated with BCNU, etoposide, cytarabine and melphalan (BEAM) and autologous stem cell transplant (ASCT). One hundred and forty-eight patients with NHL (n = 112) or HD (n = 36) received BEAM followed by infusion of bone marrow (n = 55), peripheral blood stem cells (n = 79) or both (n = 14). Twenty-eight patients had low-grade lymphoma (LGL), 68 intermediate- and 16 high-grade lymphoma (IGL). Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of ⩾2 adverse prognostic features at diagnosis or to a slow CR. Of the HD patients at transplant 17 had active disease, 16 were in ⩾2 CR and three in 1st CR. The overall percentage of toxic deaths was 5.4%, while in the group of patients transplanted with PBSC it was only 1.3%. NHL patients: 78% were in CR following ASCT, including 25 out of 45 patients (56%) who were transplanted with active disease. Only two of the 11 patients transplanted with resistant disease achieved CR. Incidence of overall survival (OS) and disease-free survival (DFS) at 3 years was 65 and 75%, respectively. As far as histology was concerned, OS was significantly better for patients with LGL in comparison with IGL (88 vs 56%) (P = 0.002). DFS was significantly higher for patients transplanted in first CR or first partial remission (PR) than it was for those transplanted in a later CR or PR (86 vs 53%) (P = 0.02). Multivariate analysis for OS showed that histology, bulky disease, poor performance status at transplant and achievement of CR were independent prognostic factors. In addition, a high number of infused MNC was associated with poor DFS. HD patients: 30 (83%) were in CR after transplantation, with 25 maintaining CR at the end of the study. Only one of the four patients transplanted with resistant disease reached CR. Incidence of OS and DFS at 3 years was 78 and 81%. DFS was similar for patients transplanted with early or late relapse (95 and 93%). With multivariate analysis, the only independent variable for OS was CR after transplant. In conclusion, the present results demonstrate the efficacy and low toxicity of the BEAM regimen in high-risk lymphoma patients with sensitive disease. Other strategies should be investigated for patients with refractory lymphoma.


Annals of Oncology | 2000

Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia

José Mariano Hernández; M.C. del Cañizo; A. Cuneo; J.L. García; Norma C. Gutiérrez; Marcos González; G. Castoldi; J. F. San Miguel

BACKGROUND Atypical chronic myeloid leukemia (aCML) is an infrequent chronic myeloproliferative disorder characterized by leukocytosis, absence of Philadelphia chromosome or BCR-ABL rearrangement, and marked myeloid dysplasia. Some cases have an absolute monocytosis but can be distinguished from chronic myelomonocytic leukemia (CMML) by the presence of a higher percentage (> 15%) of circulating immature granulocytes. PATIENTS AND METHODS In a series of 11 patients with a diagnosis of aCML according to the FAB proposals we have analyzed the most relevant clinical, hematological and cytogenetic characteristics. RESULTS The median age was 65 years (16-84). All but one case showed, at time of diagnosis, leukocytosis (median WBC was 36 x 10(9)/l), 55% had moderate anemia and 36% had thrombocytopenia. Most cases had marked dysplasia, particularly in the granulocytic lineage (82% of the cases), and all cases showed bone marrow red hypoplasia. Cytogenetic abnormalities were present in 9 out of the 11 patients. Trisomy 8 was observed in three cases and other clonal chromosomal abnormalities included deletions of 5q, 13q, 17p, 12q, and 11q as well as a t(6;8)(p23;q22) translocation. Fluorescence in situ hybridization (FISH) studies failed to demonstrate ETV-6 gene involvement. The median survival time from diagnosis was only 14 months (range 3-56 months). CONCLUSIONS These data suggest that aCML is a rare disease which is characterized by leukocytosis, with dysgranulopoiesis, BM erythroid hypoplasia, chromosomal, though not recurrent, abnormalities and poor prognosis.


British Journal of Cancer | 1993

Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.

R. García; Jm Hernandez; M. D. Caballero; González M; Josefina Galende; M.C. del Cañizo; L Vazquez; J. F. San Miguel

The efficacy of currently available treatments for Hodgkins disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.


Cell Transplantation | 2013

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

Soraya Carrancio; C. Romo; Teresa L. Ramos; Sandra Muntión; H. J. Prins; Anton Martens; Jesús G. Briñón; J. F. San Miguel; M.C. del Cañizo; F.M. Sanchez-Guijo

Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.


Bone Marrow Transplantation | 1999

Factors that influence long-term hematopoietic function following autologous stem cell transplantation

M.L. Amigo; M.C. del Cañizo; Caballero; L Vazquez; Mercedes Corral; Belén Vidriales; A Brufau; J. F. San Miguel

The aim of the present study was to assess which factors influence hematopoietic function long term after transplantation. For this purpose, we have analyzed a series of 79 patients who underwent autologous transplantation. None of them received any further chemotherapy or radiotherapy after transplant. All patients were disease-free 1 year after autologous transplantation. Late impairment of hematopoietic function was defined as the presence of non-transient peripheral blood cytopenias, detected 6 and 12 months after autografting. Before transplantion, 38.7% of patients showed peripheral blood cytopenias. Six and 12 months after transplantation, cytopenias presented in 44.2% and 42.4% of patients, respectively. Cases displaying cytopenias 6 months after transplantation had received a significantly lower dose of CFU-GM and CD34+ cells than patients without cytopenias (P = 0.012 and P= 0.04, respectively). The same correlation, with even higher statistical significance, was observed 12 months after transplant (P = 0.007 and P = 0.005). Alkylating agents and radiotherapy administered prior to transplantation and age did not seem to influence the presence of permanent cytopenias. The incidence did not vary significantly according to the stem cell source (bone marrow or peripheral blood). The number of CFU-GM and CD34+ cells infused was the most important factor for maintenance of adequate hematopoiesis.


British Journal of Haematology | 1996

A randomized study comparing the effect of GM‐CSF and G‐CSF on immune reconstitution after autologous bone marrow transplantation

J. F. San Miguel; M. D. Hernández; Marcos González; Mc Lopez-Berges; M. D. Caballero; Lourdes Vázquez; Alberto Orfao; Mj Nieto; Mercedes Corral; M.C. del Cañizo

Haemopoietic growth factors (HGFs) have been shown to accelerate recovery from severe neutropenia after autologous bone marrow transplantation (ABMT) but their effect on immune reconstitution is not well defined. The present study compares, through randomized trial, the in vivo effect of GM‐CSF and G‐CSF administration on the immune recovery of patients who underwent ABMT. For that purpose, we have sequentially analysed 14 different T, B and NK lymphoid cell subsets using appropriate dual staining during the first year following transplant (days +6, +17, +31, +66, +90, +120, +180, +360). 24 patients with lymphoproliferative disorders (20 lymphomas and four multiple myelomas) and who had undergone ABMT were included in the study. The median age was 43 years (range 22–62 years). All lymphoma patients were homogenously conditioned with BEAM. Our results show that both GM‐CSF and G‐CSF aid T‐cell (CD3+/αβ) recovery though their contribution varies depending on the T‐cell subset analysed. G‐CSF contributed to a significantly faster recovery of CD8+ cells (P=0.03). The CD8+ cell regeneration was produced mainly by activated cells (CD38+/HLA‐DR+) which lacked the CD11b antigen. In contrast, GM‐CSF favoured the regeneration of CD4+ cells (through both the CD45RO+ and CD45RA+ subset), leading to a higher CD4+:CD8+ ratio (P=0.007). No statistically significant differences were detected in the three groups of patients as regards both the recovery of NK cells and NK activity. Furthermore, the use of HGF did not seem to exert a significant influence on the recovery of B lymphocytes. This recovery was based on the CD5+ subpopulation that showed a rapid rise after the first month. We suggest that G‐CSF and GM‐CSF not only influence myeloid recovery, but also regeneration of the immune system after ABMT.


Transfusion Medicine | 2012

Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use.

Sandra Muntión; F.M. Sanchez-Guijo; Soraya Carrancio; Eva Villaron; O. López; M. Diez-Campelo; J. F. San Miguel; M.C. del Cañizo

Purpose: The aim of this study was to optimise the yield of metaphases in mesenchymal stromal cells (MSC) in vitro cultures and to study the karyotype of MSC expanded in good manufacturing practice (GMP) conditions for clinical use.


Leukemia | 2014

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

Sergio Matarraz; Bruno Paiva; M. Diez-Campelo; Susana Barrena; María Jara-Acevedo; María Laura Gutiérrez; J M Sayagués; M-L Sánchez; Paloma Bárcena; M P Garrastazul; M J Berruezo; J M Duran; Carlos Cerveró; J A García-Erce; Lourdes Florensa; G D Méndez; Oliver Gutiérrez; M.C. del Cañizo; J J M van Dongen; J. F. San Miguel; Alberto Orfao

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations


Recent results in cancer research | 1993

Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia.

Alberto Orfao; Belén Vidriales; González M; Mc Lopez-Berges; M.C. del Cañizo; J. F. San Miguel

Acute myeloblasts leukemia (AML) is known to have highly variable clinical and biological characteristics. In recent years the availability of monoclonal antibodies (MAbs) specific for the different myeloid lineages and their differentiation stages, together with the development of new highly sensitive techniques such as flow cytometry, have both provided new insights into the biology of AML and contributed to more accurate diagnosis and classification of these leukemia patients (Ball 1990; Drexler and Minowada 1986; Goasguen and Bennett 1990; Ludwig and Thiel 1990; Neame et al. 1986; Pessano et al. 1984; San Miguel et al. 1986b; Second MIC Cooperative Group Study 1988; Van der Reijden et al. 1983). Although there is only a limited amount of data available, some studies (Ball et al. 1991; Campos et al. 1989; Geller et al. 1990; Griffin et al. 1986; San Miguel et al. 1989; Schwarzinger et al. 1990) suggest that the immunophenotype might also be of help in the prognostic evaluation of AML patients.


Leukemia | 1998

CLONAL MYELODYSPLASTIC CELLS PRESENT IN APHERESIS PRODUCT BEFORE TRANSPLANTATION

M.L. Amigo; M.C. del Cañizo; Jm Hernandez; M. Gonzalez; Norma C. Gutiérrez; M.V. Mateos; J. F. San Miguel

phomas are transformed into large cell lymphomas they no longer need T cell stimulation to maintain their continuous progression; however, while they are lymphomas of low-grade malignancy they need stimulation from HP-specific T cells. This hypothesis explains the tendency for gastric MALT lymphomas to stay in the stomach where HP provides antigenic stimulation, and it also explains why elimination of HP is sometimes effective in causing MALT lymphomas of lowgrade malignancy to regress. In the current case, the number of mutations observed was almost identical with that of the expected value, as shown in Table 2, calculated as it occurs at random. This indicated proliferation of lymphoma cells not selected by any specific antigenic stimulation, in other words, no specific variant of a lymphoma clone was growing. This must be one of the important reasons why this tumor spread widely without being transformed to a large cell-type high-grade lymphoma. Such lymphoproliferative disorders may arise not only in gastric tissue but also in other mucosal areas such as ocular, bronchial and prostatic regions. The term ‘pseudolymphoma’ has been used for those disorders, such as ‘RLH’ in the stomach. Recent studies using Southern blot analysis demonstrated that they consist of monoclonal B cell proliferation leading to diagnoses of lymphomas with low-grade malignancy. In addition to gastric cases, proliferation of MALT lymphomas in other organs may correlate with some specific antigenic stimulation. Thus, it would be of great value to consider this concept in detail with the aim of developing a new and effec-

Collaboration


Dive into the M.C. del Cañizo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M.L. Amigo

University of Salamanca

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

L Vazquez

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

N Lopez

University of Salamanca

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

González M

Universidad Autónoma de Nuevo León

View shared research outputs
Researchain Logo
Decentralizing Knowledge